First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): A feasibility study and comparative analysis of the SCOTROC series

European Journal of Cancer

Volumn 46, Issue 11, 2010, Pages 2020-2026

  Agarwal, Roshan ^a,b   Gourley, Charlie ^c   Perren, Timothy J ^d   Reed, Nicholas ^e   Parkin, David E ^f   Carty, Karen ^e   Rustin, Gordon J S ^g   Gabra, Hani ^b   Paul, Jim ^e   Gore, Martin E ^a   Kaye, Stanley B ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^g MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Carboplatin; Gemcitabine; Ovarian cancer; Paclitaxel; Sequential therapy

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EDEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; HEADACHE; HOT FLUSH; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PAIN; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 77954212827     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.03.006     Document Type: Article

References (19)

1. M. Harries, C. Moss, and T. Perren A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer Br J Cancer 91 2004 627 632
2. W.P. McGuire, W.J. Hoskins, and M.F. Brady Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6
3. M.J. Piccart, K. Bertelsen, and K. James Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 2000 699 708
4. A. du Bois, H.J. Luck, and W. Meier A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J Natl Cancer Inst 95 2003 1320 1329
5. J.P. Neijt, S.A. Engelholm, and M.K. Tuxen Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer J Clin Oncol 18 2000 3084 3092
6. R.F. Ozols, B.N. Bundy, and B.E. Greer Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
7. A. du Bois, B. Weber, and J. Rochon Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens J Clin Oncol 24 2006 1127 1135
8. M.A. Bookman, M.F. Brady, and W.P. McGuire Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup J Clin Oncol 27 2009 1419 1425
9. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
10. F.M. Muggia, P.S. Braly, and M.F. Brady Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study J Clin Oncol 18 2000 106 115
11. A.R. Clamp, J. Maenpaa, and D. Cruickshank SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer Br J Cancer 94 2006 55 61
12. P.A. Vasey, R. Atkinson, and R. Osborne SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer Br J Cancer 94 2006 62 68
13. S. Bhatia, N. Hanna, and R. Ansari A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer Lung cancer 38 2002 73 77
14. A.L. Thomas, G. Cox, and R.A. Sharma Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study Eur J Cancer 36 2000 2329 2334
15. G.J. Rustin, M. Quinn, and T. Thigpen Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) J Natl Cancer Inst 96 2004 487 488
16. P.A. Vasey, G.C. Jayson, and A. Gordon Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma J Natl Cancer Inst 96 2004 1682 1691
17. M. Friedlander, M. Buck, and D. Wyld Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer Int J Gynecol Cancer 17 2007 350 358
18. N. Katsumata, M. Yasuda, and F. Takahashi Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial Lancet 374 2009 1331 1338
19. M.A. Bookman Dose-dense chemotherapy in advanced ovarian cancer Lancet 374 2009 1303 1305